Next generation drugs

The successful clinical application of RTK-based therapeutics in the last 8 years instigates further research to generate the next generation drugs. Thus, antisense RNAs or dominant-negative receptor mutants are being tested for their ability to reduce receptor expression. 

The field is now poised to move into a new phase that will address opportunities for improvement on the profiles of RAL and EVG. These "next generation" drugs will need to deliver notable advantages in resistance profile along with having a high genetic barrier to resistance [51,52]. 

It is possible that QSAR, an empirical correlation of the data, may provide a pharmacophoric model that will be useful in next-generation drug design within this class. In such an approach, it is hoped that many of the factors which define antimalarial potency can be correlated with the structures of the analogues, and the resulting model, if valid, could be used as a predictive tool. 

Bialy, L., Waldmann, H. Inhibitors of protein tyrosine phosphatases next-generation drugs . Angeiv. Chem. Int. Ed. 2005, 44, 3814—3839. 

Grube, E., Buellesfeld, L. BioMatrix Biohmus A9-eluting coronary stent a next-generation drug drug-eluting stent for coronary artery disease. Expert Rev. Med. Dev. 3, 731-741 (2006)... 

TRADITIONAL KIDNEY SAFETY PROTEIN BIOMARKERS AND NEXT-GENERATION DRUG-INDUCED KIDNEY INJURY BIOMARKERS IN NONHUMAN PRIMATES... 

Udipi, K., Chen, M., Cheng, R, et al. Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. J. Biomed. Mater. Res. A 85A, 1064-1071 (2008). doi 10.1002/jbm.a.31664... 

Palladino MA, Bahjat FR, Theodorakis EA et al (2003) Anti-TNF-alpha therapies the next generation. Nat Rev Drug Discov 2 736-746... 

The development of sialidase-based inhibitors as anti-influenza drugs has provided a first line-of-defence to safeguard humanity against a potential pandemic and most importantly to buy time for vaccine and further anti-influenza drug development. Most exciting is that new opportunities exist for next generation sialidase inhibitor development. 

Cutler NR and Sramek JJ (2001). Review of the next generation of Alzheimer s disease therapeutics Challenges for drug development. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 25, 27-57. 

---